Salix Pharmaceuticals, Ltd. engages in the acquisition, development, and commercialization of prescription drugs used in the treatment of various gastrointestinal diseases in the United States. Its products include Colazal capsules for the treatment of ulcerative colitis; Xifaxan, which is a gastrointestinal-specific oral antibiotic for the treatment of travelers’ diarrhea caused by noninvasive strains of E coli in patients of 12 years of age and above; Visicol tablets and OsmoPrep tablets for cleansing the bowel as a preparation for colonoscopy; and Azasan, a drug that suppresses immune system responses and is indicated for preventing rejection of kidney transplants and treatment...